author-photo

Vince B. C. Biemans

Radboud University Nijmegen

15

Papers

102

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease.

2021 European Journal of Gastroenterology & Hepatology
Show All
- Source
- Cite
- Save
Citations (0)
Letter: tofacitinib in treatment-refractory ulcerative colitis-a single centre real-world experience in Australia. Authors' reply.

2021 Alimentary Pharmacology & Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
P340 Comorbidity is associated with safety outcomes in vedolizumab- and ustekinumab-treated inflammatory bowel disease patients

2020 Journal of Crohns & Colitis
Show All
- Source
- Cite
- Save
Citations (0)
Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti‐TNF failure—getting closer to the truth. Authors' reply

2020 Alimentary Pharmacology & Therapeutics
Show All
- Source
- Cite
- Save
Citations (1)
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.

2020 Alimentary Pharmacology & Therapeutics
Show All
- Source
- Cite
- Save
Citations (21)
Tofacitinib, two-faced Janus in ulcerative colitis and Crohn's disease?

2020 United European gastroenterology journal
- Vince B. C. Biemans
- Bram Verstockt
Show All
- Source
- Cite
- Save
Citations (0)
Ustekinumab for Crohn’s disease: results of the ICC Registry, a nationwide prospective observational cohort study

2019 Journal of Crohns & Colitis
Show All
- Source
- Cite
- Save
Citations (58)